XXII 22nd Century Group Inc.

22nd Century Group (Nasdaq: XXII) Partners With Eagle Rock Distributing Company to Place VLN® in Thousands of Retail Locations Across Colorado

22nd Century Group (Nasdaq: XXII) Partners With Eagle Rock Distributing Company to Place VLN® in Thousands of Retail Locations Across Colorado

  • Partnership Will Bring Reduced Nicotine Content Cigarettes to New Regional and National Chains and Independent Accounts Statewide
  • Eagle Rock Is a Wholesaler for Anheuser-Busch With Deep Expertise In the Colorado Retail Market

BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that starting in September the Company will initiate placement for VLN® reduced nicotine cigarettes in thousands of accounts across Colorado with , a wholesale partner of Anheuser-Busch. The partnerships will bring 22nd Century’s proprietary VLN® brand premium tobacco cigarettes to new, regional and national chains, and independent accounts statewide. VLN® smokes, smells, and tastes like a cigarette but contains approximately 95% less nicotine than conventional cigarettes, a level shown to be non-addictive. As noted on the packaging, VLN® is the only cigarette in the world purposefully designed to “Help You Smoke Less.”

In addition to 22nd Century’s retail partnerships with Circle K, one of the largest convenience chains in North America, and Smoker Friendly®, a leading pioneer in the cigarette and tobacco store category, with more than 800 independently owned and operated retail stores, 22nd Century’s diverse channel of partners will enable the Company to expand its sales reach throughout the state of Colorado. Eagle Rock services almost any location alcoholic beverages are sold, including drug stores such as Walgreens, grocery stores such as Safeway, convenience store chains such as Circle K and 7-Eleven, independent retail stores, military points of sale, and duty free and travel retail. The decision to launch in Colorado follows the exceptional pilot results in Chicago, keeping with 22nd Century’s plans to have distribution and retail partnerships in place to support the expanding availability of VLN® to adult smokers across the country. The Chicago pilot demonstrated that in-store outreach was highly effective, and once adult smokers had tried VLN®, the vast majority were quick to recommend VLN® to other adult smokers.

“We’re thrilled to partner with Eagle Rock as we open VLN® sales across Colorado. In addition to our existing retail partnerships from our Chicago pilot, we now have access to nearly 7,000 prospective new locations through Eagle Rocks’ network, to include both on premise and off premise locations,” said John J. Miller, president of 22nd Century’s Tobacco Business. “We’ll be working together with Eagle Rock’s talented team of close to 500 employees to get the message out about how VLN® can ‘help you smoke less’. Eagle Rock’s team will also handle all sales, service, and promotional activities for our VLN® brand.”

“We are excited to partner with 22nd Century Group to market VLN® across the State of Colorado. We want Colorado to be the first State to have a combustible cigarette brand that meets the U.S. Food and Drug Administration (FDA) and Biden Administration’s proposed nicotine cap broadly available to adult smokers across the state to truly help them smoke less,” said Michael Economos, President of Eagle Rock Distributing Company. “We have had similar ‘nonalcoholic’ adult beverage offerings for decades, and we are way overdue for adult cigarette smokers to have an analogous option.”

With over 90 years of history, Eagle Rock Distributing Company is a leading beverage distributor of premium alcoholic beverages servicing license retailers across Georgia and Colorado. Eagle Rock distributes brands from the likes of Anheuser-Busch, Yuengling, New Belgium, Monday Night Brewing, Essentia, Nestle, Barrell Bourbon, Scotto Cellars and most recently the Sazerac Company of Brands, to name a few and is a wholesale partner of Anheuser-Busch.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200



EN
20/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Group’s GVB Biopharma Opens New Central Distribution Faci...

22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands New distribution facility supports rapidly growing demand for hemp/cannabis products BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- , a 22nd Century Group company (Nasdaq: ), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon...

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022. “We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Inve...

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences: On Tuesday, November 15, 2022, the Company will host one-on-one meetings at the Roth 2nd Annual AgTech Answers Event.On Thursday, November 17, 2022, the Company will ho...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Fina...

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022 Accelerating VLN® Sales in Colorado and Illinois, Launching in Four Corners States to Capture Market Share and VolumeGVB Biopharma Acquisition Growing Revenue on Increased VolumesThird Quarter Net Sales $19.4 Million, Up 148% from the Third Quarter 2021Strong Balance Sheet to Support Strategic Initiatives Including Accelerated VLN® Expansion BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicate...

 PRESS RELEASE

New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarett...

New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation Reduced nicotine cigarettes increase cessation, decrease consumption, decrease dependence, and reduce toxicantsStudy dispels common misconception that reduced nicotine cigarettes worsen general health and mental health problems BUFFALO, N.Y., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch